Inovio Pharmaceuticals Inc (Inovio) is a biotechnology company that focuses on developing DNA immunotherapies and vaccines for the treatment and prevention of various cancers and infectious diseases. The company develops products based on its core SynCon DNA plasmid technology and electroporation delivery technology. Its product pipeline includes VGX-3100 for the treatment of cervical HSIL, vulvar HSIL, anal HSIL; INO-5401 for glioblastoma; INO-3107 for recurrent respiratory papillomatosis (RRP); and INO-5151 for prostate cancer. The company is also engaged in development programs in partnership with several companies and government bodies to develop therapeutics for infectious diseases such as HIV, Ebola, Zika virus, Middle East respiratory syndrome (MERS), Lassa fever and COVID-19. Inovio is headquartered in Plymouth Meeting, Pennsylvania, the US.
Headquarters
United States of America
Address
6769 Mesa Ridge Rd., San Diego, California, 92121
Website
www.inovio.com
Telephone
1 858 4103134
No of Employees
317
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
INO (NASD)
Revenue (2020)
$1.8M
-76.1%
(2020 vs 2019)
EPS
XXX
Net Income (2020)
XXX
-82.5%
(2020 vs 2019)
Market Cap*
$540.5M
Net Profit Margin (2020)
XXX
-662.0%
(2020 vs 2019)
* As of and is in US$
Access premium data and analytics for Inovio Pharmaceuticals Inc
Products and Services
| Products | Brands |
|---|---|
| Pipeline products: | dMAb |
| COVID-19: | SynCon |
| INO-4800 | Cellectra |
| XXX | |
| XXX | |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Regulatory Approval | In November, the company received approval from the Drug Controller General of India for Phase III trial of the Covid-19 vaccine, INO-4800, in India. |
| 2021 | Contracts/Agreements | In November, the company entered into a collaboration with Geneva University Hospitals and GuardRX for the clinical trial of its Ebola DNA vaccine candidate, INO-4201. |
| 2021 | Contracts/Agreements | In October, the company entered into a memorandum of understanding with Colombia's Ministry of Health and Social Protection to combat Coronavirus disease. |
Competitor Comparison
| Key Parameters | Inovio Pharmaceuticals Inc | Pfizer Inc | Merck & Co Inc | GSK plc | Sanofi |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United Kingdom | France |
| City | San Diego | New York | Kenilworth | Brentford | Paris |
| State/Province | California | New York | New Jersey | - | - |
| No. of Employees | 317 | 79,000 | 68,000 | 90,096 | 95,442 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Simon X. Benito | Chairman | Executive Board | 2019 | 77 |
| Jacqueline E. Shea, Ph.D. | Chief Executive Officer; President | Senior Management | 2022 | - |
| Peter D. Kies | Chief Financial Officer | Senior Management | 2002 | 58 |
| Michael Sumner | Chief Medical Officer | Senior Management | 2022 | - |
| Laurent Humeau, Ph.D. | Chief Scientific Officer | Senior Management | 2019 | 55 |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer